Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapoxetine + vitamin B12 is a combination therapy investigated for the treatment of premature ejaculation. Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that increases serotonin activity in the synaptic cleft, thereby delaying ejaculation. Vitamin B12 (cobalamin) is an essential water-soluble vitamin involved in methylation reactions and neurotransmitter synthesis; it may enhance serotonergic and noradrenergic function, potentially augmenting the efficacy of SSRIs like dapoxetine. Clinical studies suggest that patients with higher serum vitamin B12 levels respond better to dapoxetine, and supplementation with vitamin B12 may improve outcomes in those with deficiency or suboptimal response to dapoxetine monotherapy[2][3][4]. The combination has been evaluated in randomized controlled trials for premature ejaculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dapoxetine + vitamin b12.